MedTrace Logo

Study of CBP501/Cisplatin/Nivolumab Combinations in Advanced Pancreatic Cancer

NCT04953962 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2023-08-15

No results posted yet for this study

Summary

Multicenter, randomized, open-label, parallel group phase 2 study to assess the efficacy and tolerance of four combinations of CBP501, cisplatin, and nivolumab administered once every 21 days to patients with stage IV exocrine pancreatic cancer and WBC \< 10,000/mm3 at screening.

Conditions

  • Pancreatic Cancer Stage IV

Interventions

DRUG

CBP501 (16)

16 mg/m2

DRUG

CBP501 (25)

25 mg/m2

DRUG

Cisplatin

60mg/m2

DRUG

Nivolumab

240 mg

Sponsors & Collaborators

  • CanBas Co. Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-18
Primary Completion
2023-04-14
Completion
2023-04-14
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04953962 on ClinicalTrials.gov